- Home
- ARQT vs VTEX Comparison
ARQT vs VTEX Comparison
Compare ARQT & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- VTEX
- Stock Information
- Founded
- ARQT 2016
- VTEX 1999
- Country
- ARQT United States
- VTEX Cayman Islands
- Employees
- ARQT N/A
- VTEX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- VTEX Computer Software: Prepackaged Software
- Sector
- ARQT Health Care
- VTEX Technology
- Exchange
- ARQT Nasdaq
- VTEX Nasdaq
- Market Cap
- ARQT 2.1B
- VTEX 742.4M
- IPO Year
- ARQT 2020
- VTEX 2021
- Fundamental
- Price
- ARQT $17.14
- VTEX $4.57
- Analyst Decision
- ARQT Strong Buy
- VTEX Strong Buy
- Analyst Count
- ARQT 7
- VTEX 4
- Target Price
- ARQT $19.00
- VTEX $7.63
- AVG Volume (30 Days)
- ARQT 1.5M
- VTEX 1.3M
- Earning Date
- ARQT 11-05-2025
- VTEX 11-04-2025
- Dividend Yield
- ARQT N/A
- VTEX N/A
- EPS Growth
- ARQT N/A
- VTEX 48.79
- EPS
- ARQT N/A
- VTEX 0.05
- Revenue
- ARQT $263,464,999.00
- VTEX $230,497,000.00
- Revenue This Year
- ARQT $72.46
- VTEX $10.61
- Revenue Next Year
- ARQT $31.69
- VTEX $14.33
- P/E Ratio
- ARQT N/A
- VTEX $87.46
- Revenue Growth
- ARQT 99.50
- VTEX 4.53
- 52 Week Low
- ARQT $8.03
- VTEX $3.92
- 52 Week High
- ARQT $18.15
- VTEX $7.58
- Technical
- Relative Strength Index (RSI)
- ARQT 59.14
- VTEX 57.22
- Support Level
- ARQT $16.62
- VTEX $4.03
- Resistance Level
- ARQT $18.15
- VTEX $4.14
- Average True Range (ATR)
- ARQT 0.69
- VTEX 0.12
- MACD
- ARQT 0.01
- VTEX 0.11
- Stochastic Oscillator
- ARQT 66.89
- VTEX 94.24
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.